Cirrhosis, CLD complication, fatty liver disease Flashcards

You may prefer our related Brainscape-certified flashcards:
1
Q

List causes of cirrhosis

A
  • Alcoholic liver disease
  • Nonalcoholic fatty liver disease (fatty liver)
  • Hepatitis B
  • Hepatitis C
  • Drugs
  • Ethanol **
  • Fatty liver
  • Genetic: copper, alpha-1 antitrypsin deficiency
  • Haemochromatosis
  • Immune: AIH (Autoimmune Hepatitis), PBC (Primary Biliary Cholangitis), PSC (Primary Sclerosing Cholangitis)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

DESCRIBE CLiiical featurs of cirrhosis

A
  • spider naevi
  • palmar erythema
  • ascites
  • white nails/leuconychia

Hepatic damage–>insufficiency:
- coma
- jaundice
- liver damage
- anaemia
- haemorrhage
- oedema
- ascites –also portal hypertension
- note hepatic damage also results in hyperestrinism, causing spider naevi, gynaecomastia, pectoral alopecia, altered hair distribution, palmar erythema and testicular atrophy
- portal hypertension
- oeso varices
- splenomegaly
- caput medusae
- ascites
- ankle oedema
- hyperspenism–> bone marrow changes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Routes to mortality from liver disease

A
  • Bleed (varices)
  • Infection (spontaneous bacterial peritonitis)
  • Cancer (HCC - Hepatocellular Carcinoma)
  • Coma (encephalopathy)
  • Renal failure
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Describe ascites, relationship to liver disease, and how to determine if ascites, infection, neoplastic process involved

A
  • 85% (cirrhotic)
  • 15% (non-cirrhotic)
    • Renal
    • Cardiac
    • Peritoneal metastasis

Ascites: Questions to Ponder
- Is it cirrhotic ascites?
- SAAG (Serum albumin - ascites albumin gradient) > 11 g/L indicates portal hypertension
- Is there infection?
- Neutrophils > 250/cu.mm
- Is there cancer?
- Cytology

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Describe pathophysiology of ascites

A

see also [[Gastroenterology - Lecture 5]]
- renal retention of sodium
- reduced effective arterial blood volume (due to stiffliver)
- activates RAAS, SNS, ADH
- Na, H2O retention and increased plasmavolume
- compartmentalisation of fluid to peritoneal cavity
- increased hydrostatic pressure due to stiff liver, lymphatic flow
—-> ascites

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Describe management of ascites

A
  • Salt restriction (2 g/day)
  • Diuretics:
    • Start with spironolactone - due to high aldo conc
    • Add frusemide
  • Monitor weight, U&E, urine sodium to prevent complications from diurtic use
  • No need to restrict fluid (unless Na+ below 120)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

describe treatment of diuretic-resistant ascites

A
  • Definition: Ascites not responding to max doses or adverse effects develop/not tolerated
  • Large volume paracentesis with albumin (supplement Albumin 8-10 g/litre fluid removed)
    • To prevent postparacentesis circulatory dysfunction
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Describe sbp

A
  • Signs: Often none, nonspecific; diagnosis by ascitic fluid test - WCC >250–> antibiotics
  • Treatment: IV antibiotics (e.g., ceftriaxone) for 5 days
  • Prevention: Prophylactic oral antibiotics if there is a history of SBP; in patients with GI bleed
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Descrieb hepatic encephalopathy

A
  • Impaired neuropsychiatric syndrome due to acute or chronic liver disease
  • Hepatic encephalopathy in essence: ammonia intoxication as a result of portal shunting to brain, altering mental state
    • ammonia end-product of protein metabolism in intestine, due to bacteria
    • shunted to liver, normal de-toxxed to urea and excreted
    • Grades I (mild confusion, non-specific, poor sleep, ‘night watchman- awake at night, asleep in day’) to IV (coma)
      • FLAP/Asterixis - more prominent in GII/III - unlikely in GI
      • neuropsychiatric symptoms worsens in III
    • STROOP TEST/psychometric number connection tests (timed test)
      • can be used to check response to treatment
  • Remember!
    • There are other causes of confusion: SDH, sedating drugs and meds, hyponatremia, hypoglycaemia, withdrawal delirium from alcohol or Wernicke’s
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Describe hepatic encephalopathy management

A
  • Treat precipitating factors (infection, drugs, constipation, hypokalaemia, GI bleeding) -> helps improve encephalopathy
  • Lactulose (MAIN STAY)
    • How does it work?
      • Acidifies gut (reduces ammonia)
      • Inhibits ammonia-forming bacteria
      • Acts as a laxative
  • Antibiotics: Sterilize gut - if not responsive to lactulose
    • Rifaximin
    • Metronidazole
    • Neomycin (historical)
  • combination of lactulose and antibiotics may be useful, eg if lactulose poorly tolerated ie patient becomes bloating
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What are other consequences of cirrhosis?

A
  • Kidneys: Hepatorenal syndrome (decreased blood flow)
  • Lungs: Hepatopulmonary syndrome (rare), portopulmonary hypertension
  • Grading of cirrhosis severity
    • CHILD-PUGH score, MELD score -
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Describe varices and their significance

A
  • back flow of blood into portal vein tributaries
  • eg stiff liver —> left gastric and oesophageals anastomoses at GEJ; rectal anastomoses and haemorrhoids

Varices - Why Are They Important?
- Most (80%) cirrhotics will develop varices.
- Main cause of upper GI bleeding in cirrhosis (peptic ulcer, other causes less often).
- High mortality from bleed and rebleed (SCREEN ALL CIRRHOTICS).
- use platelet count, liver stiffness measurements i.e. fibroscan to screen

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Describe management of varices

A
  • Prevent: Prevent bleeding through banding or drugs that lower portal pressure (propranolol, carvedilol - beta blocker with alpha blocking action, may be useful in liver specifically). ^[avoid non-selective drugs in asthmatics]
  • Bleeding: Treat bleeding with banding + drugs that lower portal pressure (octreotide IV/infusion - somatostatin analog).
  • Prevent Re-Bleeding: Prevent re-bleeding through banding.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Descrieb managing acute bleeding from varices

A
  • Bleeding can be SEVERE.
    • Protect airway e.g. intubation, aim for Hb 80 g/L.
  • Administer antibiotics and lactulose.
    • SBP (Spontaneous Bacterial Peritonitis) and encephalopathy are common after a bleed.
    • Antibiotics also reduce rebleeding risk.
  • Start octreotide (reduces splanchnic flow).
  • Endoscopy
    ##### Endoscopic Variceal Ligation (EVL)
  • EVL is 90% effective for control of acute bleeding.- done monthly until all variceal columns targeted
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

List alternatives to endoscopy

A
  • If endoscopy fails:
    • Balloon Tamponade: Sengstaken-Blakemore tube – OCCLUDE varices.
    • Transjugular Intrahepatic Portosystemic Shunt (TIPS): DIVERT BLOOD.
    • Surgery: Very rare now.

Sengstaken-Blakemore Tube (Balloon Tamponade)
- compress haemorrhaging vessels to occlude
#### Transjugular Intrahepatic Portosystemic Shunt (TIPS)
- DIVERT BLOOD.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Describe HCC, its relatinshup to cirrhosis and howearly tumours and detected

A

Hepatocellular Carcinoma (HCC)
- Cirrhosis of any cause (especially alcohol, hepatitis B and C) but can occur in absence of cirrhosis eg HepB, fatty liver
- usually ID’d by imaging eg U/S, CT
- Suspect HCC when there is weight loss, abdominal pain/mass, jaundice, or ascites.- but do not wait for these as these are signs of advanced disease

How to Detect Early Tumours
- Imaging: Ultrasound first, CT or MRI later, every 6 months.
- Tumour Marker: Alpha feto-protein (AFP).

Liver Imaging
- eg ultrasound, CT, in conjunction with AFP
- AFP (Alpha Feto-Protein)
- Produced by the fetal liver.
- Increased in 60% of cases.- absence does not exclude cancer
- Can be increased in other disorders (testicular tumours, (viral) hepatitis because it is a marker of liver regeneration).

17
Q

Describe course of fatty lvier disease and increased susceptibility factors to liver injury from alcohol

A
  • from fatty liver to alcoholic hepatitis to cirrhosis, alternatively straight to cirrhosis
    • all heavy drinkers will have fat in liver
    • fewer develop hepatitis, even fewer progress to cirrhosis
  • Increased susceptibility to liver injury from alcohol:
    • Women
    • Other liver disorders (e.g., Hepatitis C)
    • Metabolic syndrome: obesity, diabetes
    • Genetic factors: genes involved in immune response, cytokines
18
Q

Discuss sex differences in alcohol threshold for liver injury

A
  • Men: 60-80 g/day x 5 years
  • Women: 20 g/day
  • Less than 20% of men who ingest 2 six-packs/day for 10 years end up with cirrhosis.
    • sex difference alcohol threshold for injury; lower alcohol can still precipitate cirrhosis in men
19
Q

Describe clinical presentation fo fatty lvier

alc

A
  • Asymptomatic
  • Enlarged, soft liver (fatty liver)
  • Fever, jaundice, leukocytosis (hepatitis – will distinguish from eg HepB, see also [[Gastroenterology - Lecture 11]])
  • Features of cirrhosis: jaundice, ascites, GI bleeding, encephalopathy
20
Q

List relevant investigations in fatty liver disease

A
  • Clinical suspicion important (CAGE)
  • FBC/LFT: Anaemia, high MCV (direct effect of alcohol + B12+ folate), AST > ALT, GGT
  • Other signs of advanced liver disease:
    • Bilirubin, low albumin, coagulopathy, low platelets
21
Q

escribe principles of treatment for fatty liver disease

alcohol

A
  • No alcohol.
  • Nutritional supplements: thiamine, B12, folate
  • Corticosteroids (in severe alcoholic hepatitis).- only s-term, first 4 weeks therapy. Long-term does not improve outcomes
  • Managing cirrhosis complications (AFP, liver ultrasound, endoscopy- looking for varices).
  • Liver transplant (abstinence > 6 months, good social support demonstrated).
22
Q

Describe relationship between alcohol and lvier disease

A
  • Safe limits important but liver risk variable.
  • Clinical spectrum: asymptomatic, big liver, “hepatitis”, cirrhosis/liver failure.
  • Suspicion important: MCV, AST > ALT.
  • Fatty liver reversible, hepatitis can progress, cirrhosis can progress.
  • Treatment: stop drinking, supplements, steroids, rarely liver transplant.
23
Q

Describe the specteum of MAFLD

A

Spectrum
- Healthy liver
- Fatty liver (Steatosis) >5% vol - at this stage, <1d/d women, <2 in men
- Steatohepatitis (N/MASH)
- Cirrhosis - irreversible step
- HCC either from MASH, or cirrhosis
- Alcohol-like liver histology in persons who don’t drink significant amounts of alcohol.

Fatty Liver - Spectrum

  • Lobular inflammation
  • Ballooning degeneration
  • Perivenular fibrosis
24
Q

What is the significance of MAFLD?

A
  • 30%
  • Advanced liver disease in a subgroup [age >45, obesity, diabetes].- screen
  • Co-factor for other liver diseases.
    • Increased cardiovascular risk^[significant contributor to mortality], diabetes mellitus.
  • HCC risk.
25
Q

DESCRIBE MAFLD pathogenesis

A
  • Main underlying mechanism: insulin resistance.
  • mAFLD is the hepatic manifestation of the metabolic syndrome.
  • Other important processes: lipotoxicity, oxidative stress, adipocytokines, mitochondrial defects, genetic factors.
26
Q

Describe MAFLD clinical presentation

A
  • Asymptomatic
  • Abnormal ultrasound, liver tests
    • ALT > AST
  • Enlarged, soft liver
  • Advanced liver disease not common
  • Look for metabolic syndrome: hypertension, type 2 diabetes, central obesity
27
Q

Descrieb MAFLD natural history

A
  • Overall, 5% of mAFLD develop cirrhosis, 1.7% die of cirrhosis complications (mean follow-up 7 years).
  • Simple steatosis: benign outcome.
  • mASH: One-third will progress (fibrosis).
  • Cirrhosis 5%-10% over 5 years.
  • Poor outcome of mASH-related cirrhosis.
28
Q

Describe MAFLD principles of treatment

A
  • lifestyle modification- aerobic and resistance exercise, eg Med diet; engaging personal trainer/dietitian/family support
  • targeting MetS components
  • liver-directed pharmacotherapy- only one recent drug, not mainstay
  • managing complications of cirrhosis
  • Impact of Weight Loss on Improving Fatty Liver
    • steatosis 35-100 - w/ weight loss >=103
    • ballooning/inflammation 41-100 - w/ weight loss >=5
    • NASH resolution in 64-90% - w/ weight loss >=7
    • fibrosis in 45% - w/ weight loss >=10
29
Q

List other MAFLD treatments

A
  • bariatric sg when done for other metabolic disease
  • semaglutide no effect on fibrosis, steatosis; only in context of diabetes
  • other drugs not licensed except resmeritrom (thyroid hormone b-receptor), pioglitazone, vitamin E